CURRENT
ISSUE
1568

A lidocaine 1.8% patch (ZTlido – Scilex) has been approved by the FDA for treatment of pain associated with postherpetic neuralgia (PHN). A lidocaine 5% patch (Lidoderm, and generics) was approved earlier for the same indication and has been used off-label for treatment of other types of localized pain. Both of these patches are available only by prescription. Lidocaine 4% patches (Aspercreme, IcyHot, and others) are available over the counter for back, neck, shoulder, and joint pain.

POSTHERPETIC NEURALGIA — About 20-30% of patients ≥60 years old with herpes zoster...  Continue reading

More from Issue 1568
Previous Issue: 1567      March 11, 2019
Coming Soon
Drugs for Heart Failure
Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression
PrabotulinumtoxinA (Jeuveau) for Frown Lines
OTC Drugs for Seasonal Allergies
Ozenoxacin Cream (Xepi) for Impetigo
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
FROM
ISSUE
1568

Sarecycline (Seysara – Allergan), a new oral tetracycline antibiotic, has been approved by the FDA for once-daily treatment of inflammatory lesions of non-nodular moderate to severe acne in patients ≥9 years old.

STANDARD TREATMENT — Initial treatment of inflamed acne lesions usually includes benzoyl peroxide and/or a topical retinoid, with or without a topical antibiotic such as erythromycin or clindamycin.1,2

For moderate to severe inflammatory acne that does not respond to topical combination therapy, addition of an oral tetracycline is recommended because of its dual antibacterial and anti-inflammatory effects. Treatment with doxycycline or minocycline, usually for 3-4 months, is preferred.1,2 Long-term ... Continue reading